Bronchodilators remain the cornerstone of the treatment of airway disorders such as asthma
and chronic obstructive pulmonary disease (COPD). There is therefore considerable interest …

Highlights•Dual bronchodilator therapy has clinical benefits in COPD.•Combining a LABA
with a LAMA synergistically relaxes medium and small airways.•In some approved …

Introduction: Heart failure (HF) with reduced ejection fraction and chronic obstructive
pulmonary disease (COPD) frequently coexist, particularly in the elderly. Given their rising …

Objective Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …

Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …

Background: Long-acting muscarinic antagonists (LAMAs) and long-acting β2–agonists
(LABAs) are the mainstay of maintenance therapy for chronic obstructive pulmonary disease …

Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory
disease and its prevalence is increasing worldwide, in both industrialised and developing …

Objective The combination of a long-acting muscarinic antagonist (LAMA) and a long-acting
β2-agonist (LABA) in a single inhaler is a viable treatment option for patients with chronic …

A majority of existing studies have focused on the efficacy of inhaled long-acting
bronchodilators (ILABs), such as long-acting muscarinic antagonists (LAMAs) and long …

AZD8871 is a novel muscarinic antagonist and β 2-adrenoceptor agonist in development for
chronic obstructive pulmonary disease. This study describes the pharmacological profile of …